Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: Do the latest trials challenge existing evidence?

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Mallat, Samir G ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme (ACE) inhibitors; Blood pressure; Cardiovascular disease; Direct renin inhibitors; Dual renin angiotensin system inhibition; Outcomes; Renal disease

Indexed keywords

ALISKIREN; AMLODIPINE; CANDESARTAN; CAPTOPRIL; ENALAPRIL; EPLERENONE; IRBESARTAN; LERCANIDIPINE; LOSARTAN; NIFEDIPINE; PLACEBO; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; AUGMENTATION INDEX; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MACROALBUMINURIA; META ANALYSIS (TOPIC); MONOTHERAPY; MORBIDITY; MULTICENTER STUDY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROTEINURIA; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SMOKING CESSATION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFECTS; EVIDENCE BASED MEDICINE; KIDNEY DISEASES; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; TREATMENT OUTCOME;

EID: 84880334666     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-108     Document Type: Review

References (123)

1. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004, 116(4):263-272. 10.1016/j.amjmed.2003.09.034, 14969655.
2. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991, 121(4 Pt 1):1244-1263.
3. Fliser D. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease. J Nephrol 2010, 23(4):369-376.
4. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006, 20(5):953-970. 10.1210/me.2004-0536, 16141358.
5. Sata M, Fukuda D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J Med Invest 2010, 57(1-2):12-25.
6. Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010, 31(6):541-550. 10.1159/000313363, 3202956, 20484892.
7. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins B, Gordon MS, Williams GH, Laffel LM. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003, 63(1):172-178. 10.1046/j.1523-1755.2003.00701.x, 12472780.
8. Taniwaki H, Ishimura E, Kawagishi T, Matsumoto N, Hosoi M, Emoto M, Shoji T, Shoji S, Nakatani T, Inaba M, Nishizawa Y. Intrarenal hemodynamic changes after captopril test in patients with type 2 diabetes: a duplex Doppler sonography study. Diabetes Care 2003, 26(1):132-137. 10.2337/diacare.26.1.132, 12502669.
9. Farsang C. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag 2011, 7:605-622. 3212426, 22102784.
10. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006, 368(9545):1449-1456. 10.1016/S0140-6736(06)69442-7, 17055947.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345(12):851-860. 10.1056/NEJMoa011303, 11565517.
12. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358(23):2433-2446. 10.1056/NEJMoa0708379, 18525041.
13. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn S, Zhang Z, Shahinfar S. Effects of losartan on renaland cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869. 10.1056/NEJMoa011161, 11565518.
14. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358(6):580-591. 10.1056/NEJMoa0706245, 18256393.
15. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345(12):870-878. 10.1056/NEJMoa011489, 11565519.
16. Basi S, Fesler P, Mimran A, Lewis JB. Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander?. Diabetes Care 2008, 31(Suppl 2):S194-S201.
17. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329(20):1456-1462. 10.1056/NEJM199311113292004, 8413456.
18. Parving HH, Hovind P. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep 2002, 4(5):387-393. 10.1007/s11906-002-0069-3, 12217258.
19. Strippoli GF, Craig MC, Schena FP, Craig JC. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol 2006, 17(4 Suppl 2):S153-S155.
20. AIRE study investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993, 342(8875):821-828. AIRE study investigators.
21. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351(20):2058-2068. 2556374, 15531767.
22. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325(5):303-310. 10.1056/NEJM199108013250502, 2057035.
23. CONSENSUS study investigators Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316(23):1429-1435. CONSENSUS study investigators.
24. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362(9386):782-788.
25. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333(25):1670-1676. 10.1056/NEJM199512213332503, 7477219.
26. Maggioni AP. Measuring the occurrence of myocardial infarction. Eur Heart J 1999, 20(9):634-635.
27. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327(10):669-677. 10.1056/NEJM199209033271001, 1386652.
28. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de WF, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349(20):1893-1906. 10.1056/NEJMoa032292, 14610160.
29. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349(9054):747-752. 10.1016/S0140-6736(97)01187-2, 9074572.
30. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355(9215):1582-1587. 10.1016/S0140-6736(00)02213-3, 10821361.
31. SOLVD investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325(5):293-302. SOLVD investigators.
32. SOLVD study investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992, 327(10):685-691. SOLVD study investigators.
33. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358(15):1547-1559.
34. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360(9335):752-760. 10.1016/S0140-6736(02)09895-1, 12241832.
35. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000, 57(5):1803-1817. 10.1046/j.1523-1755.2000.00031.x, 10792600.
36. Kintscher U, Unger T. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers. Acta Diabetol 2005, 42(Suppl 1):S26-S32.
37. Munger MA. Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T 2011, 36(1):22-40. 3046622, 21386934.
38. Halabi CM, Sigmund CD. Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis: mechanisms and clinical implications. Am J Cardiovasc Drugs 2005, 5(6):389-398. 10.2165/00129784-200505060-00006, 16259527.
39. Verges B. Clinical interest of PPARs ligands. Diabetes Metab 2004, 30(1):7-12. 10.1016/S1262-3636(07)70083-6, 15029092.
40. Trimarchi H. Role of aliskiren in blood pressure control and renoprotection. Int J Nephrol Renovasc Dis 2011, 4:41-48. 3108787, 21694948.
41. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007, 50(11):2398-2404. 10.1007/s00125-007-0795-9, 17828524.
42. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Muller DN. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005, 46(3):569-576. 10.1161/01.HYP.0000179573.91016.3f, 16103264.
43. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993, 118(8):577-581. 10.7326/0003-4819-118-8-199304150-00001, 8452322.
44. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997, 349(9069):1857-1863.
45. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000, 355(9200):253-259.
46. Chan C, Poulter N, Scanlon M, Whitehouse A, Welsh P, Sattar N, Sever P. on behalf of the ASCOT investigators The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) biomarker programme. J Hypertens 2011, 29:e17-e18. on behalf of the ASCOT investigators.
47. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007, 30(6):1577-1578. 10.2337/dc06-1998, 17389334.
48. Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007, 30(6):1351-1356. 10.2337/dc06-1551, 17337492.
49. Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Ryden L, Yu CM, Teo KK, Yusuf S. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009, 151(1):1-2. 10.7326/0003-4819-151-1-200907070-00122, 19451556.
50. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002, 106(6):672-678. 10.1161/01.CIR.0000024416.33113.0A, 12163426.
51. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005, 45(5):880-886. 10.1161/01.HYP.0000161880.59963.da, 15809363.
52. Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007, 72(7):879-885. 10.1038/sj.ki.5002455, 17667984.
53. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362(9386):772-776. 10.1016/S0140-6736(03)14284-5, 13678870.
54. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362(9386):767-771. 10.1016/S0140-6736(03)14283-3, 13678869.
55. Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009, 53(6):468-470. 10.1016/j.jacc.2008.10.036, 19195602.
56. Messerli FH, Staessen JA, Zannad F. Of fads, fashion, surrogate endpoints and dual RAS blockade. Eur Heart J 2010, 31(18):2205-2208. 10.1093/eurheartj/ehq255, 20685681.
57. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321(7274):1440-1444. 10.1136/bmj.321.7274.1440, 27545, 11110735.
58. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362(9386):759-766. 10.1016/S0140-6736(03)14282-1, 13678868.
59. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362(9386):777-781. 10.1016/S0140-6736(03)14285-7, 13678871.
60. Epstein M. Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease. Nat Clin Pract Nephrol 2009, 5(1):12-13.
61. Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009, 4(2):361-368. 10.2215/CJN.03350708, 2637584, 19118120.
62. Volpe M, Danser AH, Menard J, Waeber B, Mueller DN, Maggioni AP, Ruilope LM. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?. J Hypertens 2012, 30(4):647-654. 10.1097/HJH.0b013e32834f6e00, 22278139.
63. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372(9638):547-553. 10.1016/S0140-6736(08)61236-2, 18707986.
64. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1(1):17-24. 10.1161/CIRCHEARTFAILURE.107.740704, 19808266.
65. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif PC, Smith BA, Dahlof B. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119(4):530-537. 10.1161/CIRCULATIONAHA.108.826214, 19153265.
66. McMurray JJ, Abraham WT, Dickstein K, Kober L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012, 14(4):341-343. 10.1093/eurjhf/hfs033, 3307357, 22431404.
67. Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, McMurray JJ, Pfeffer MA. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J 2011, 32(10):1227-1234. 10.1093/eurheartj/ehq522, 21317148.
68. Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013, 309(11):1125-1135. 10.1001/jama.2013.1954, 23478743.
69. National PBM Bulletin Dual renin-angiotensin aldosterone system blockade in diabetic nephropathy and increased adverse events 2013, December 2; Available at: URL: [http://www.pbm.va.gov/vacenterformedicationsafety/nationalpbmbulletin/DualRenin-AngiotensinAldosteroneSystemBlockadeandImpairedRenalFu.pdf], National PBM Bulletin.
70. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372(9644):1174-1183.
71. Grandi AM, Solbiati F, Laurita E, Maresca AM, Nicolini E, Marchesi C, Gianni M, Guasti L, Venco A. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am J Hypertens 2008, 21(2):231-237. 10.1038/ajh.2007.47, 18174880.
72. Cice G, Di Benedetto A, D'Isa S, D'Andrea A, Marcelli D, Gatti E, Calabro R. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010, 56(21):1701-1708. 10.1016/j.jacc.2010.03.105, 21070920.
73. Miyazaki S, Kasai T, Miyauchi K, Miyazaki T, Akimoto Y, Takagi A, Aihara K, Kawamura M, Suwa S, Kojima S, Sumiyoshi M, Daida H. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. Circ J 2010, 74(6):1158-1164. 10.1253/circj.CJ-09-0412, 20378999.
74. Pouleur AC, Uno H, Prescott MF, Desai A, Appelbaum E, Lukashevich V, Smith BA, Dahlof B, Solomon SD. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2011, 12(4):483-490. 10.1177/1470320311414453, 21746765.
75. Pitt B, Latini R, Maggioni AP, Solomon SD, Smith BA, Wright M, Prescott MF, McMurray JJ. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Eur J Heart Fail 2011, 13(7):755-764. 10.1093/eurjhf/hfr034, 21467028.
76. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008, 14(3):181-188. 10.1016/j.cardfail.2007.11.008, 18381180.
77. Kuenzli A, Bucher HC, Anand I, Arutiunov G, Kum LC, McKelvie R, Afzal R, White M, Nordmann AJ. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS One 2010, 5(4):e9946. 10.1371/journal.pone.0009946, 2848587, 20376345.
78. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):145-153.
79. Basevi V, Di Mario S, Morciano C, Nonino F, Magrini N. Standards of medical care in diabetes-2011. Diabetes Care 2011, 34(Suppl 1):S11-S61. 3006050, 21193625.
80. Krause MW, Fonseca VA, Shah SV. Combination inhibition of the renin-angiotensin system: is more better?. Kidney Int 2011, 80(3):245-255. 10.1038/ki.2011.142, 21633407.
81. Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011, 123(10):1098-1107. 10.1161/CIRCULATIONAHA.110.964171, 21357827.
82. Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008, 52(3):475-485. 10.1053/j.ajkd.2008.03.008, 18468748.
83. Robles NR, Ruiz JB, Hernandez GR, Ruiz-Calero R, Sanchez CE, Cubero JJ. Dual renin-angiotensin system blockade: in patients with single functioning kidney and proteinuria. Eur J Intern Med 2009, 20(2):186-189. 10.1016/j.ejim.2008.06.002, 19327610.
84. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148(1):30-48. 10.7326/0003-4819-148-1-200801010-00190, 17984482.
85. Szeto CC, Kwan BC, Chow KM, Leung CB, Li PK. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy - a randomized cross-over study. PLoS One 2013, 8(5):e62736. 10.1371/journal.pone.0062736, 3651209, 23675422.
86. Lizakowski S, Tylicki L, Rutkowski P, Renke M, Sulikowska B, Heleniak Z, Donderski R, Bednarski R, Przybylska M, Manitius J, Rutkowski B. Safety of the enhanced renin-angiotensin-aldosteron system blockade with aliskiren in nondiabetic patients with chronic kidney disease. Pol Arch Med Wewn 2013, 123(5):221-227. Epub Apr 25.
87. Cheng J, Zhang X, Tian J, Li Q, Chen J. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract 2012, 66(10):917-923. 10.1111/j.1742-1241.2012.02970.x, 22994326.
88. McAlister FA, Zhang J, Tonelli M, Klarenbach S, Manns BJ, Hemmelgarn BR. The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis. CMAJ 2011, 183(6):655-662. 10.1503/cmaj.101333, 3071385, 21422125.
89. Remission Clinic Task Force The Remission Clinic approach to halt the progression of kidney disease. J Nephrol 2011, 24(3):274-281. Remission Clinic Task Force.
90. Kurnik D, Vesterman-Landes J, Bialik M, Katzir I, Lomnicky Y, Halkin H, Loebstein R. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting. Clin Ther 2011, 33(4):456-464. 10.1016/j.clinthera.2011.04.011, 21635991.
91. Frimodt-Moller M, Hoj NA, Strandgaard S, Kamper AL. Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease. Nephrol Dial Transplant 2010, 25(3):842-847. 10.1093/ndt/gfp547, 19903661.
92. Frimodt-Moller M, Kamper AL, Strandgaard S, Kreiner S, Nielsen AH. Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease-a randomized trial. PLoS One 2012, 7(7):e41757. 10.1371/journal.pone.0041757, 3409235, 22860014.
93. Bilic M, Munjas-Samarin R, Ljubanovic D, Horvatic I, Galesic K. Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria. Coll Antropol 2011, 35(4):1061-1066.
94. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis 1998, 137(Suppl):S65-S73.
95. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001, 44(Suppl 2):S14-S21.
96. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van ZP, Waeber B, Williams B. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25(6):1105-1187. 10.1097/HJH.0b013e3281fc975a, 17563527.
97. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, Van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009, 18(6):308-347. 10.3109/08037050903450468, 20001654.
98. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20(8):1813-1821. 10.1681/ASN.2008121270, 2723977, 19443635.
99. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362(17):1563-1574. 2879499, 20228404.
100. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367(23):2204-2213. Epub Nov 3, 10.1056/NEJMoa1208799, 23121378.
101. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E, Parving HH. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009, 32(10):1873-1879. 10.2337/dc09-0168, 2752919, 19587362.
102. Mann JF, Anderson C, Gao P, Gerstein HC, Boehm M, Ryden L, Sleight P, Teo KK, Yusuf S. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens 2013, 31(2):414-421. 10.1097/HJH.0b013e32835bf7b0, 23249829.
103. Bakris GL, Oparil S, Purkayastha D, Yadao AM, Alessi T, Sowers JR. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2013, 15(2):92-100.
104. Abe M, Maruyama N, Suzuki H, Fujii Y, Ito M, Yoshida Y, Okada K, Soma M. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria. Hypertens Res 2012, 35(8):874-881. 10.1038/hr.2012.45, 22592665.
105. Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, Oude Ophuis AJ, Lopez-Sendon J, Swedberg K, Ogorek M, Rifai N, Lukashevich V, Maboudian M, Cannon CP, McCabe CH, Braunwald E. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J 2010, 31(16):1993-2005. 10.1093/eurheartj/ehq190, 20558431.
106. Ishibashi K, Kurisu S, Kato Y, Mitsuba N, Dohi Y, Nishioka K, Kihara Y. Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker. Hear Vessel 2013, 28(1):7-11.
107. Wong J. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed. Diab Vasc Dis Res 2013, 10(3):193-201. 10.1177/1479164112463710, 23349369.
108. Baker WL, Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R, Phung OJ, White CM. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 2009, 151(12):861-871. 10.7326/0000605-200912150-00162, 20008762.
109. Ravid M. Dual blockade of the renin-angiotensin system in diabetic nephropathy. Diabetes Care 2009, 32(Suppl 2):S410-S413. 2811448, 19875590.
110. Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF, Gao P, Craig JC, Tognoni G, Perkovic V, Nicolucci A, De Cosmo S, Sasso A, Lamacchia O, Cignarelli M, Manfreda VM, Gentile G, Strippoli GF. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2011, 26(9):2827-2847. 10.1093/ndt/gfq792, 21372254.
111. Cherney DZ, Scholey JW, Jiang S, Har R, Lai V, Sochett EB, Reich HN. The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes. Diabetes Care 2012, 35(11):2324-2330. 10.2337/dc12-0773, 22837362.
112. Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, Beyene J, Shah PS. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 2012, 344:e42. 10.1136/bmj.e42, 3253766, 22232539.
113. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013, 346:f360. 10.1136/bmj.f360, 3556933, 23358488.
114. Catala-Lopez F, Macias Saint-Gerons D. Diabetes mellitus and risks of dual blockade of the renin-angiotensin-aldosterone system. Rev Esp Cardiol 2013, 66(5):412-415. 10.1016/j.recesp.2012.11.010, 23427897.
115. St Peter WL, Odum LE, Whaley-Connell AT. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. Pharmacotherapy 2013, 33(5):496-514. 10.1002/phar.1232, 23576066.
116. Messerli FH, Bangalore S. ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point. Am J Med 2013, 126(3):e1-e3. 10.1016/j.amjmed.2012.07.006, 23885679.
117. Veglio F, Puglisi E, Milan A, Mulatero P. Combinations of renin-angiotensin-aldosterone system antagonists: true advantages?. Curr Pharm Des 2012, 18(7):952-957. 10.2174/138161212799436566, 22283773.
118. CHEP Canadian recommendations for the management of hypertension 2012, Available at: URL: [http://toolkit.cfpc.ca/en/files/2012_CHEPRecsBooklet_EN_HCP1030.pdf] Accessed May 28, 2013, CHEP.
119. UK Medicines Information What is the rationale and evidence for combining angiotensin converting enzyme inhibitors with angiotensin II receptor blockers in renal disease? NHS 2012 January 7; Available at: URL: [https://www.evidence.nhs.uk/], UK Medicines Information.
120. Aliskiren Prescribing Information Available at: URL: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021985s023lbl.pdf] Accessed November 16, 2012, Aliskiren Prescribing Information.
121. Aliskiren SmPC EMA 2013, Available at: URL: [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000780/WC500047010.pdf] Accessed 2013, Aliskiren SmPC.
122. EMA Review started of combined use of renin-angiotensin system (RAS)-acting agents 2013, May 16; Available at: URL: [http://www.emea.europa.eu/docs/en_GB/document_library/Referrals_document/Renin-angiotensin_system_(RAS)-acting_agents/Procedure_started/WC500143500.pdf], EMA.
123. Mallat SG. What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?. Cardiovasc Diabetol 2012, 11:32. 10.1186/1475-2840-11-32, 3351968, 22490507.